Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent ...
Strategy spent a whopping $1.28 billion to buy 17,994 more bitcoin last week, raising its total holdings to 738,731 BTC worth about $50 billion at current prices. Strategy, the bitcoin treasury ...
Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based ...
STRC scaled to an aggregate stated amount of $3.4 billion, with a current dividend rate of 11.25% $413 million in cumulative distributions paid, representing a blended annual dividend rate of 9.6% ...
TYSONS CORNER, Va.--(BUSINESS WIRE)--Strategy Inc (Nasdaq: STRF/STRC/STRK/STRD/MSTR; LuxSE: STRE) (“Strategy”) today announced that, for U.S. federal income tax ...
HERCESSI™ becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...
Fintel reports that on December 22, 2025, Citigroup maintained coverage of Strategy Inc - Preferred Stock (NasdaqGS:STRF) with a Buy recommendation. Analyst Price Forecast Suggests 213.83% Upside As ...
Fintel reports that on December 22, 2025, Citigroup maintained coverage of Strategy Inc - Preferred Stock (NasdaqGS:STRF) with a Buy recommendation. As of December 21, 2025, the average one-year price ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Andres Almiray, a serial open-source ...
Fintel reports that on December 8, 2025, Bernstein maintained coverage of Strategy Inc - Preferred Stock (NasdaqGS:STRF) with a Outperform recommendation. Analyst Price Forecast Suggests 193.43% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results